Kinfo
iBio, Inc. logo

iBio, Inc.

IBIONASDAQHealthcare·US · USD
$0.71
-0.02 (-2.74%)
Prices as of November 16, 2026 · market closed

Price

Key statistics

Valuation
Market cap46.94M USD
Enterprise value-23.03M USD
Trailing P/E0.59
Forward P/E-1.40
PEG ratio-1.40
Price / sales47.96
Price / book0.60
Profitability
Gross margin0.00%
Operating margin-3025.58%
Profit margin0.00%
Return on assets-26.61%
Return on equity-51.82%
Income (TTM)
Revenue1.07M USD
Gross profit1.07M USD
EBITDA-31.93M USD
Net income-34.88M USD
Diluted EPS-$0.27
Rev. growth (YoY)975.00%
Balance sheet
Total cash76.65M USD
Total debt2.07M USD
Debt / equity2.63
Current ratio9.48
Book value / share$1.22
Cash flow (TTM)
Operating cash flow-26.94M USD
Levered free cash flow-19.56M USD
Shares & price
Shares outstanding55.70M
Float50.52M
Held by institutions62.05%
Beta0.00
50-day MA$0.98
200-day MA$1.62
52-week high$3.82
52-week low$0.69
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-11-10-0.08-0.05+37.50%2026-08-28-0.06-0.07−16.67%2026-07-280.870.89+2.30%2026-06-11-0.33-0.09+72.73%2026-02-10-0.06-0.09−50.00%
About iBio, Inc.

iBio, Inc. is a biotechnology company focused on developing precision antibodies and other next-generation biologics for obesity, cardiometabolic disease, cancer, and other hard-to-treat conditions. The company uses artificial intelligence, advanced computational biology, and proprietary discovery platforms to identify and optimize antibody candidates against challenging therapeutic targets. Its current technology stack includes platforms designed for antibody engineering, masking, optimization, and epitope steering, which support preclinical research and early-stage pipeline development. iBio’s work is centered on improving the speed and precision of drug discovery for complex diseases, with an emphasis on antibody-based therapies and related biopharmaceutical programs. Founded in 2008 and headquartered in San Diego, California, iBio plays a niche role in the biotechnology market as a research-driven company advancing AI-enabled biologic discovery.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Martin B. Brenner D.V.M., Ph.D.
Employees
23
Headquarters
San Diego, CA, United States

Frequently asked questions about iBio, Inc.